Outgoing Treasury Secretary Steven Mnuchin and Secretary of State Michael Pompeo briefly discussed removing President Donald Trump through the 25th Amendment after the Jan. 6, 2021, Capitol attack but rejected the idea, according to a transcript of Mnuchin’s testimony.
Australian shares are set to end 2022 as one of the region’s more resilient markets after eye-watering gains from mining firms offered shelter from a global rout.
Global bonds fell in thin trading on concern China’s decision to relax coronavirus curbs would spur inflation.
The tailspin in Tesla Inc. shares accelerated Tuesday, marking their longest losing streak since 2018, as a report of a plan to temporarily halt production at its China factory rekindled fears about demand risks.
New York Governor Kathy Hochul signed a bill on Friday that allows the state’s and New York City’s pensions to increase allocations to more expensive and opaque asset classes like private equity that could potentially deliver higher returns.
Apple Inc. shares closed at their lowest level since June 2021 on Tuesday, amid an ongoing selloff of big-tech stocks amplified by concerns over iPhone supply in the key holiday period.
(Bloomberg) — Oil clung to a three-week high as storm-hit US refineries restarted and China’s further easing of travel restrictions promised to bolster demand.
Southwest Airlines Co. canceled almost two-thirds of its flights Tuesday, still hobbled by a massive winter storm that most major rivals were able to recover from with greater ease.
The deep freeze that blanketed most of the US in the past few days killed dozens and temporarily plunged millions into darkness. Yet the country narrowly escaped an even worse calamity as natural gas and power supplies buckled across several states, laying bare just how vulnerable the electric grid has become to a full-on catastrophe.
A tiny Tokyo-based diagnostics firm that developed the first US-approved spinal fluid test for Alzheimer’s is now doubling down on developing blood tests — an easier method to detect the brain-wasting disease against which a blockbuster therapy is expected soon.
